Collectively, these findings illustrate the notable effectiveness of the concurrent use of PD-L1 blocking with CHK1 or PARP inhibition, thereby establishing a robust scientific justification for the integration of these approaches in clinical studies involving individuals with SCLC. This evidence concerns the gene CHEK1 and small cell lung carcinoma.